There are three announcements in this post. The next meeting (1 paragraph), Clinical Trials (2 pages) and Abraxane (1 page).
The next meeting for the Silicon Valley Affiliate of the Pancreatic Cancer Action Network is Wednesday 18 September at 6:30 PM at the Sports Basement in Campbell (SE corner of Bascom and Hamilton). The meeting is in the Community Room at the north end of the Sports Basement. We hope to see you there!
Find out what's happening in San Ramonfor free with the latest updates from Patch.
I apologize for disjointed prose as Copy/Paste killed format and broke links.
Find out what's happening in San Ramonfor free with the latest updates from Patch.
Please add "communications@pancan.org" to your Email Address Book. Learn how.
leadership
MESSAGE
The guest columnist this month is Jordan Berlin, MD. Dr. Berlin is the Ingram Professor of Cancer Research,
Co-Director of Gastrointestinal Oncology and Director of Phase I Research at the Vanderbilt University Medical Center in Nashville, Tenn. Read more.
join us for
AN EVENING WITH THE STARS GALA
on October 19.
Learn more.
end of summer
SALE
Check out the ShopPurple end of summer sale!
keep the
MEMORY ALIVE
Create an honorary tribute page for your loved one and help everyone affected by pancreatic cancer.
CLINICAL TRIALS
Analyzing the Landscape to Increase Progress
Pancreatic Cancer Action Network publishes a comprehensive clinical trials analysis in a prestigious medical journal. Learn more.
MORE THAN $5.1 MILLION IN RESEARCH GRANTS AVAILABLE
Applications are now being accepted for more than $5.1 million in pancreatic cancer research grants.
Learn more or apply.
$1.4 MILLION GIFT FUNDS IMPORTANT RESEARCH
Three Pancreatic Cancer Action Network research grants funded by Janet Mordecai in honor of her late husband, Daniel, carry promising scientists into their second year of work.
Learn more.
CLINICAL TRIALS ARE KEY TO PROGRESS
Clinical trials open the doors to new treatment options and create hope for patients diagnosed with pancreatic cancer. Learn more.
FDA APPROVES ABRAXANE®
New treatment option is now available for patients with advanced pancreatic cancer.Read more.
upcoming
EVENTS
SEPTEMBER MEETINGS & EVENTS
Albuquerque
Anchorage
Boise
Denver
Inland Northwest
Jackson
Las Vegas
Los Angeles
Montana
Oahu
Orange County
Phoenix
Portland
Puget Sound
Sacramento
Salt Lake City
San Diego
San Francisco Bay Area
Silicon Valley
PURPLESTRIDE
San Diego - 10/13
Portland - 11/2
Sacramento - 11/2
Silicon Valley - 11/2
Puget Sound - 11/3
Orange County - 11/9
CORE VOLUNTEERS NEEDED
Los Angeles
Portland
Puget Sound
San Diego
San Francisco Bay Area
Silicon Valley
For information about including the Pancreatic Cancer Action Network in your estate planning, click here.
**FDA APPROVES ABRAXANE® IN COMBINATION WITH GEMCITABINE FOR TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC CANCER**
Dear Richard,
Today the U.S. Food and Drug Administration (FDA) approved the use of ABRAXANE®, when combined with the chemotherapy drug gemcitabine, to treat patients with advanced pancreatic cancer that has spread from its original site. This important drug approval follows the results of the phase III clinical trial announced in January by the pharmaceutical company Celgene. This is the first new treatment approved to treat pancreatic adenocarcinoma, the most common type of pancreatic cancer, in nearly eight years.
The Pancreatic Cancer Action Network is pleased about this important step forward in a disease that desperately needs treatment advances. We will continue to work with the medical community to build upon this success and reach our goal to double survival from pancreatic cancer by 2020.
The trial data showed that overall survival increased by nearly two months (8.5 vs. 6.7) in patients who received ABRAXANE and gemcitabine, when compared to gemcitabine alone. A 59 percent increase in one-year survival was also reported.
Clinical trial participation enables treatment advances and gives patients access to state-of-the-art care. We recommend that patients discuss clinical trials with their physician each time a treatment decision is made. The Pancreatic Cancer Action Network is the leading resource for pancreatic cancer clinical trial information and maintains the most comprehensive and up-to-date database of pancreatic cancer clinical trials in the U.S. We simplify the process of finding clinical trials through our Patient and Liaison Services (PALS) program. PALS Associates provide personalized clinical trials searches, free of charge. Contact PALS, Monday through Friday from 7 a.m. to 5 p.m., Pacific Time at 877-272-6226 or PALS@pancan.org.
Sincerely,
Julie Fleshman, JD, MBA
President and CEO
